Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Cyanidin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 5/20 | 1.00 |
| ▸ | SNCA | P37840 | 3/20 | 1.00 |
| ▸ | DPP4 | P27487 | 3/20 | 1.00 |
| ▸ | CD38 | P28907 | 11/20 | 0.97 |
| ▸ | F2 | P00734 | 2/20 | 0.97 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.97 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.97 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.77 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | KDR | P35968 | 2/20 | 0.71 |
| ▸ | EP300 | Q09472 | 2/20 | 0.71 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanidin SCHEMBL29547214 | 1.00 | GLO1 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL7931530 | 0.98 | GLO1 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL1230940 | 0.98 | GLO1 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL29414396 | 0.98 | CD38 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL20799 | 0.98 | CD38 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL29742342 | 0.97 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL30423220 | 0.97 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL608392 | 0.97 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL1644900 | 0.97 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL6042006 | 0.95 | GLO1 (0.91) | GLO1SNCADPP4CD38F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 741 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694699-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VitaKey Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4642472-A1 | PLANT HYDROETHANOLIC EXTRACTS | O SIGMA CELL AND GENETIC LLC (US) | 2025-11-05 | — | — | EP | claimed |
| US-12383799-B2 | Golf balls having unique effect pigments in one or more layers | ACUSHNET COMPANY (US) | 2025-08-12 | — | — | US | claimed |
| WO-2025047832-A1 | SKIN COSMETIC COMPOSITION CONTAINING BOTRYOCOCCENE AS ACTIVE INGREDIENT | フィコケミー株式会社 | 2025-03-06 | — | — | WO | claimed |
| WO-2024216228-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VITAKEY INC. (US) | 2024-10-17 | — | — | WO | claimed |
| US-12089886-B2 | Cryogenic applicator | DUTCH RENEWABLE ENERGY B.V. (NL) | 2024-09-17 | — | — | US | claimed |
| WO-2024141931-A1 | PLANT HYDROETHANOLIC EXTRACTS | O SIGMA CELL AND GENETIC LLC (US) | 2024-07-04 | — | — | WO | claimed |
| US-20240198183-A1 | GOLF BALLS HAVING UNIQUE EFFECT PIGMENTS IN ONE OR MORE LAYERS | JPMORGAN CHASE BANK, N.A. | 2024-06-20 | — | — | US | claimed |
| EP-3682831-B1 | CRYOGENIC APPLICATOR | DUTCH RENEWABLE ENERGY B V (NL) | 2024-05-08 | — | — | EP | claimed |
| WO-2023167248-A1 | NEW PEST CONTROL METHOD TARGETING RESPIRATORY ORGAN FORMING MECHANISM OF PESTS | 国立研究開発法人産業技術総合研究所 | 2023-09-07 | — | — | WO | claimed |
| WO-2012022659-A2 | SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITIZATION OF TUMOUR CELLS | Universitätsklinikum Freiburg (DE) | 2012-02-23 | — | — | WO | claimed |
| WO-2009128738-A2 | USE OF THE EXTRACT OF DEFATTED SEEDS OF PRIMROSE | WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) | 2009-10-22 | — | — | WO | claimed |
| US-7261857-B2 | Colorimetric artificial nose having an array of dyes and method for artificial olfaction | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-08-28 | — | — | US | claimed |
| US-6864086-B2 | Nitric oxide-scavenging system for culturing oocytes, embryos, or other cells | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2005-03-08 | — | — | US | claimed |
| US-20040213829-A1 | Dietary supplement | COLEMAN HENRY D (US) | 2004-10-28 | — | — | US | claimed |
| US-20030143112-A1 | Colorimetric artificial nose having an array of dyes and method for artificial olfaction | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-07-31 | — | — | US | claimed |
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | WILBURN MICHAEL D (US) | 2003-04-24 | — | — | US | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| EP-0869807-A2 | USE OF A MEDICAMENT AND USE OF MIXTURE OF SUBSTANCES TO PRODUCE A MEDICAMENT | Dreluso Pharmazeutika Dr. Elten & Sohn GmbH (DE) | 1998-10-14 | — | — | EP | claimed |
| WO-1997022354-A2 | USE OF A MEDICAMENT AND USE OF MIXTURE OF SUBSTANCES TO PRODUCE A MEDICAMENT | DRELUSO PHARMAZEUTIKA DR. ELTEN & SOHN GMBH (DE) | 1997-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | MAT1A, LPO, TPMT | GLO1 163/4885SNCA 880/4885DPP4 1163/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | GLO1 3228/4885SNCA 1494/4885DPP4 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.